Companies · Biotechnology

Spinal Ventures, LLC

CHANHASSEN · Biotechnology

Diligence memoA one-page analyst read on Spinal Ventures, LLC — recommendation, valuation, rhythm, risks.
$500K
Total raised · real
2
Rounds
2.8×
Latest step-up
Top 90%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Tue Oct 29 2013 00:00:00 GMT+0000 (Coordinated Universal Time)

Spinal Ventures, LLC looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.29× the median modeled value of Pre-Seed Biotechnology companies in 2013–2015 (131 peers) — value vs value, same stage and era.
  • Within the normal band (129% of peer median) for its niche.
Dormant
  • Last raise 12.7 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Spinal Ventures, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
15.8 yr record
Peak capital year was 2013 with $370K across 1 filings.
Market position
ahead of 11% of Biotechnology peers
Capital scale is ahead of 11% of Biotechnology peers; modeled value is above 29% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2013: $370K across 1 filings.
  • Largest single filing was $370K on 2013-10-29.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Spinal Ventures, LLC is one of 4291 Biotechnology companies tracked from CHANHASSEN. By capital raised it ranks in the long tail (ahead of 11% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2010-08-30 Raised $130K (real) Modeled valuation $7.2M (est)$130K$7.2MPre-Seed2010Pre-Seed · 2013-10-29 Raised $370K (real) Modeled valuation $20M (est)$370K$20MPre-Seed2013+$370KCumulative $500K

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$130K · 2010
Pre-Seed extension$370K · 2013

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$20.4M
Base estimate est.
$197K
Conservative case
$231.8M
Upside case
$2.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $7.2M · 2010-08-302010Pre-Seed · modeled $20.4M · 2013-10-292013
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
6.0 yr
Elapsed time used
12.7 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
38 mo
Avg between rounds
$158K/yr
Capital velocity
15.8 yr
On record since
2010
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$500K
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.9× of median
This company$370K
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.3× of median
This company$20.4M
Sector median$64.2M

Raised more than 11% of sector peers (real $). Modeled value above 29% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #52 of 131.

This companyCohort peer
$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Truminim, LLC · Pre-Seed Raised $1.0M · modeled $55.2M (est)Direct Spinal Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Imanis Life Sciences, LLC · Pre-Seed Raised $1.0M · modeled $55.2M (est)Universal Biosensors Inc · Pre-Seed Raised $985K · modeled $54.4M (est)One World Lab, Inc. · Pre-Seed Raised $981K · modeled $54.2M (est)Micropharma Ltd · Pre-Seed Raised $851K · modeled $47.0M (est)ConverGene LLC · Pre-Seed Raised $850K · modeled $46.9M (est)CVUS Ventures, LP · Pre-Seed Raised $850K · modeled $46.9M (est)Symbiotic Health, Inc. · Pre-Seed Raised $850K · modeled $46.9M (est)EternoGen Aesthetics, LLC · Pre-Seed Raised $939K · modeled $46.3M (est)Genomics USA, Inc. · Pre-Seed Raised $837K · modeled $46.2M (est)Immunetics, Inc. · Pre-Seed Raised $1.5M · modeled $46.1M (est)Spinal Ventures, LLC (this company) Raised $500K · modeled $20.4M (est)Spinal Ventures, LLC
CompanyStageRaised · realValue · estvs peer med.
Truminim, LLCPre-Seed$1.0M$55.2M3.48×
Direct Spinal Therapeutics, Inc.Pre-Seed$1.0M$55.2M3.48×
Imanis Life Sciences, LLCPre-Seed$1.0M$55.2M3.48×
Universal Biosensors IncPre-Seed$985K$54.4M3.43×
One World Lab, Inc.Pre-Seed$981K$54.2M3.42×
Micropharma LtdPre-Seed$851K$47.0M2.96×
ConverGene LLCPre-Seed$850K$46.9M2.96×
CVUS Ventures, LPPre-Seed$850K$46.9M2.96×
Symbiotic Health, Inc.Pre-Seed$850K$46.9M2.96×
EternoGen Aesthetics, LLCPre-Seed$939K$46.3M2.92×
Genomics USA, Inc.Pre-Seed$837K$46.2M2.92×
Immunetics, Inc.Pre-Seed$1.5M$46.1M2.91×
Spinal Ventures, LLC this companyPre-Seed$500K$20.4M1.29×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$130K2010-08-30$722K$7.2M90%
Pre-Seed$370K2013-10-29$2.1M$20.4M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$130K2010-08-30
    • First recorded raise — entered as Pre-Seed.
  2. Pre-Seed$370K2013-10-29
    • Raised again after 38 mo — slower than the ~14 mo sector norm.
    • Round 2.8× larger than the prior — scaling up.
Intelligence
2016 ~Q4
Modeled next raise · ~38mo cadence
$1.1M
Modeled next size est.range $685K$1.7M
2.8×
Last step-up
$158K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Anand Agarwal2 other2013-10
Daniel Nemes2010-08
DAN NEMES2013-10
DON KENNEDY2013-10
Paul Zwirkoski2010-08
PAUL ZWIRKOWSKI2013-10
Registry & provenance

Spinal Ventures, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1500681
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Thrivell Holdings, LlcBiotechnologyPre-Seed$500K$24.4Msame sector · same stage
Smartech Topical, Inc.BiotechnologyPre-Seed$488K$26.9Msame sector · same stage
Redbud Labs, Inc.BiotechnologyPre-Seed$520K$16.8Msame sector · same stage
Sure Retractors Inc.BiotechnologyPre-Seed$520K$14.3Msame sector · same stage
Ascendant Diagnostics LLCBiotechnologyPre-Seed$477K$26.3Msame sector · same stage
Ascent Industries Corp.BiotechnologyPre-Seed$477K$26.3Msame sector · same stage
Adulsa Therapeutics CorpBiotechnologyPre-Seed$525K$15.4Msame sector · same stage
STONE MEDICAL CorpBiotechnologyPre-Seed$525K$19.3Msame sector · same stage
Frequently asked
How much funding has Spinal Ventures, LLC raised?
Spinal Ventures, LLC has raised approximately $500K in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Spinal Ventures, LLC's estimated valuation?
Provath's modeled valuation for Spinal Ventures, LLC is approximately $20.4M (modeled range $197K–$231.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Spinal Ventures, LLC at?
Spinal Ventures, LLC's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Tue Oct 29.
What does Spinal Ventures, LLC do and where is it based?
Spinal Ventures, LLC operates in the Biotechnology sector, based in CHANHASSEN.
Explore related

See where Spinal Ventures, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Spinal Ventures, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.